Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aura Biosciences (AURA) Liabilities and Shareholders Equity (2020 - 2026)

Aura Biosciences filings provide 7 years of Liabilities and Shareholders Equity readings, the most recent being $137.7 million for Q1 2026.

  • Quarterly Liabilities and Shareholders Equity fell 11.41% to $137.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $701.5 million through Mar 2026, down 7.88% year-over-year, with the annual reading at $169.4 million for FY2025, 7.16% down from the prior year.
  • Liabilities and Shareholders Equity hit $137.7 million in Q1 2026 for Aura Biosciences, down from $169.4 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $255.1 million in Q4 2023 and bottomed at $135.0 million in Q2 2022.
  • Average Liabilities and Shareholders Equity over 5 years is $187.1 million, with a median of $190.0 million recorded in 2025.
  • The largest annual shift saw Liabilities and Shareholders Equity surged 57.82% in 2022 before it plummeted 33.88% in 2025.
  • Aura Biosciences' Liabilities and Shareholders Equity stood at $223.9 million in 2022, then rose by 13.91% to $255.1 million in 2023, then decreased by 28.45% to $182.5 million in 2024, then decreased by 7.16% to $169.4 million in 2025, then dropped by 18.74% to $137.7 million in 2026.
  • Per Business Quant, the three most recent readings for AURA's Liabilities and Shareholders Equity are $137.7 million (Q1 2026), $169.4 million (Q4 2025), and $190.0 million (Q3 2025).